SCICLONE REPORTS SECOND QUARTER 2005 RESULTS

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the second quarter and six months ended June 30, 2005. For the second quarter 2005, revenues from the sale of ZADAXIN®, SciClone's lead product, reached $6,851,000, an increase of 22% compared to revenues of $5,613,000 reported for the second quarter 2004. For the six months ended June 30, 2005, revenues totaled $13,512,000, an increase of 22% compared to revenues of $11,027,000 for the same period of 2004. The increase in revenues for the second quarter and first half 2005 is primarily attributable to an increase in the quantity of ZADAXIN sold to China, a market that accounts for approximately 90% of overall ZADAXIN sales.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=92556)